2024-513718-37-00招募中2 期
Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial
French Innovative Leukemia Organization20 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2024年8月1日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
- 试验地点
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Pr Vincent LEVY
Scientific
French Innovative Leukemia Organization
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
2 期
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage AChronic Lymphoid LeukemiaNCT03766763French Innovative Leukemia Organisation82
招募中
1 期
A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid LeukemiaAcute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12616000445471Alfred Health48
进行中（未招募）
1 期
Preemptive treatment with venetoclax plus azacitidine in patients diagnosed with acute myeloid leukemia (AML) with persistence or reappearance of measurable residual disease (MRD) after frontline chemotherapy and high-level MRD prior to allogeneic hematopoietic cell transplantation (alloHCT)CTIS2024-510648-29-00Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias29
进行中（未招募）
1 期
Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 StudyAcute Myeloid LeukaemiaMedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000273-24-GBniversity of Birmingham186
尚未招募
1 期
A Phase 1b/2 Study of the drug venetoclax in combination with induction chemotherapy(ara-c and daunorubicin)in patients with newly diagnosed or relapsed/refractory AML.CTRI/2023/02/050069All India Institute of Medical Sciences